Research Analysts Issue Forecasts for BHST Q2 Earnings

BioHarvest Sciences Inc. (NASDAQ:BHST) – Investment analysts at HC Wainwright dropped their Q2 2025 earnings estimates for BioHarvest Sciences in a report released on Monday, May 19th. HC Wainwright analyst A. Dayal now forecasts that the company will post earnings of ($0.11) per share for the quarter, down from their prior forecast of ($0.10). HC Wainwright currently has a “Buy” rating and a $14.00 target price on the stock. The consensus estimate for BioHarvest Sciences’ current full-year earnings is ($0.80) per share. HC Wainwright also issued estimates for BioHarvest Sciences’ Q3 2025 earnings at ($0.06) EPS and FY2025 earnings at ($0.30) EPS.

Separately, Craig Hallum started coverage on shares of BioHarvest Sciences in a research report on Monday, May 5th. They issued a “buy” rating and a $15.00 target price on the stock.

BioHarvest Sciences Trading Down 3.9%

Shares of NASDAQ BHST opened at $6.24 on Wednesday. The stock has a market capitalization of $102.49 million, a P/E ratio of -5.00 and a beta of 0.80. BioHarvest Sciences has a 12 month low of $6.24 and a 12 month high of $7.38. The business’s 50-day moving average price is $6.15.

BioHarvest Sciences (NASDAQ:BHST) last issued its quarterly earnings results on Thursday, May 15th. The company reported ($0.13) EPS for the quarter, topping analysts’ consensus estimates of ($0.15) by $0.02. The firm had revenue of $7.64 million for the quarter, compared to analysts’ expectations of $8.93 million.

Institutional Investors Weigh In On BioHarvest Sciences

Hedge funds have recently modified their holdings of the stock. TD Waterhouse Canada Inc. acquired a new stake in shares of BioHarvest Sciences in the fourth quarter worth approximately $69,000. True North Advisors LLC boosted its position in shares of BioHarvest Sciences by 7.6% in the first quarter. True North Advisors LLC now owns 44,391 shares of the company’s stock worth $275,000 after acquiring an additional 3,120 shares during the last quarter. Finally, Magnus Financial Group LLC boosted its position in shares of BioHarvest Sciences by 105.0% in the first quarter. Magnus Financial Group LLC now owns 71,733 shares of the company’s stock worth $444,000 after acquiring an additional 36,733 shares during the last quarter.

About BioHarvest Sciences

BioHarvest Sciences Inc is a biotech firm. It focused on leveraging its botanical synthesis technology to develop science-based and clinically proven therapeutic solutions, within business verticals nutraceutical health and wellness products such as dietary supplements and development of plant cell-based Active Pharmaceutical Ingredients which focus on specific medical indications.